WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Chiltern
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Sdcexec | April 28, 2020
Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...
PHARMA TECH
iXensor | April 28, 2022
iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...
BUSINESS INSIGHTS
PostEra | May 19, 2022
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...
ApiJect Systems Corp. | May 19, 2022
ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced today that it had completed a $111 million private round of investment. This investment round values ApiJect at approximately $300 million. The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest i...
Article
infographic
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE